NOVO HOLDINGS LAUNCHES €135M FUND TO COMBAT ANTIMICROBIAL RESISTANCE

Novo Holdings has launched the REPAIR impact fund commissioned by the Novo Nordisk Foundation. The goal is to invest into early-stage drug developers with new concepts to fight antimicrobial resistance (AMR).

Further details of the fund will be presented at 11th Berlin Conference on Novel Antimicrobials & AMR Diagnostics on 2 March, which is conducted by BIOCOM in partnership with the BEAM alliance.